BioCentury
ARTICLE | Company News

FDA approves Rituxan for pemphigus vulgaris

June 7, 2018 11:31 PM UTC

FDA approved Genentech Inc.’s Rituxan rituximab to treat moderate to severe pemphigus vulgaris. The Roche (SIX:ROG; OTCQX:RHHBY) unit said Rituxan is the first biologic approved by the agency for the disease and the first FDA-approved treatment for the indication in more than 60 years.

The chimeric mAb against CD20 antigen has breakthrough therapy and Orphan Drug status from FDA for the indication. ...

BCIQ Company Profiles

Genentech Inc.

Roche